JPMorgan lowered the firm’s price target on Ionis Pharmaceuticals (IONS) to $45 from $47 and keeps a Neutral rating on the shares. The firm ...

Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) was upgraded by analysts at StockNews.com to a “sell” rating in a ...

Ionis Pharmaceuticals (IONS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Victory Capital Management Inc. decreased its position in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS – Free Report) by 1.9% during the 4th quarter, Holdings Channel reports. The firm owned 18,004 shares ...

It has been about a month since the last earnings report for Ionis Pharmaceuticals (IONS). Shares have added about 0.1% in that time frame, outperforming the S&P 500. Will the recent positive ...

Alnylam Pharmaceuticals, Inc.’s ALNY share price has surged by 11.75%, which has investors questioning if this is right time ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with ...

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments.

Wells Fargo analyst Yanan Zhu lowered the firm’s price target on Metagenomi (MGX) to $20 from $25 and keeps an Overweight rating on the shares.